ADMABiologicshas been one of the more talked-about names in the plasma-derived biologics space this year, but the conversation in September 2026 is less about growth and more about scrutiny. After a multi-year run that turned the Ramsey, New Jersey company into a profitable specialty-immunoglobulin …
A sharp percentage pop in a sub-penny stock always draws eyes, and ADM Tronics Unlimited (OTC:ADMT) is the latest to flash one. The New Jersey-based developer of medical devices and specialty chemistries trades far below a dollar, so even a fraction of a cent …
● ADVANTIS, trading under the ticker ADVT, sits at the extreme micro end of the market, with a quoted share price measured in fractions of a cent and aMarket Valuereported at less than $100,000.
Aethlon Medical, Inc. (NASDAQ: AEMD), a micro-cap medical-device developer, drew attention after its shares slid in a single session, according to market-data feeds. The move landed as the company continues to push its lead Hemopurifier device through an early-stage oncology study and shore up …
● Abeona Therapeutics has completed one of the harder transitions in biotech: moving from a development-stage gene-therapy company to one with an approved product generating revenue.
Volatility is a familiar feature for small clinical-stage drug developers, and ABVC BioPharma, Inc. (NASDAQ: ABVC) is no exception. The Nasdaq-listed biopharmaceutical company, which is advancing a spread of mid-stage candidates across cancer, neuropsychiatry and blood disorders, has seen its shares swing sharply this …
Actuate Therapeutics, Inc (NASDAQ:ACTU) presents an unusually stark contrast: encouraging new cancer data on one side, a looming cash crunch on the other. Just as the clinical-stage biotech published fresh preclinical results supporting its lead drug elraglusib, its own filings warned that cash could …
A double-digit single-session gain in a stock as small as AccuStem Sciences Inc (OTC:ACUT) is easy to over-interpret. With aMarket Valueof only a few million dollars and a handful of employees, the shares can move sharply on very light volume.
Few recent stories in cell therapy have turned as sharply as Adaptimmune Therapeutics plc (OTC:ADAPY)'s. A company that in 2024 launched the first FDA-approved engineered T-cell receptor therapy for a solid tumor now trades for pennies on the over-the-counter market after a 2025 delisting …
Andrew Tak Shing Lo, a Senior Managing Director at Invesco Ltd., filed a Form 4 on September 10, 2026, disclosing open market sales of common shares on September 8 and September 9, 2026.